Hepatitis C treatment from “response-guided” to “resource-guided” therapy in the transition era from interferon-containing to interferon-free regimens
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatitis C treatment from “response-guided” to “resource-guided” therapy in the transition era from interferon-containing to interferon-free regimens
Authors
Keywords
-
Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 32, Issue 8, Pages 1436-1442
Publisher
Wiley
Online
2017-01-26
DOI
10.1111/jgh.13747
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
- (2017) Paul Kwo et al. GASTROENTEROLOGY
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
- (2017) Pierre Nahon et al. GASTROENTEROLOGY
- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan
- (2017) Pei-Chien Tsai et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
- (2016) Paul Kwo et al. HEPATOLOGY
- Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection
- (2016) Armand Abergel et al. HEPATOLOGY
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
- (2016) Vincent Leroy et al. HEPATOLOGY
- APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
- (2016) Masao Omata et al. Hepatology International
- APASL consensus statements and recommendation on treatment of hepatitis C
- (2016) Masao Omata et al. Hepatology International
- Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
- (2016) Jordan J. Feld et al. JOURNAL OF HEPATOLOGY
- Hepatitis C virus infection in Taiwan: Past, present, and future
- (2016) Jia-Horng Kao JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study
- (2016) Armand Abergel et al. LANCET INFECTIOUS DISEASES
- Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
- (2016) Ming-Ying Lu et al. Oncotarget
- High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
- (2015) Fiona McPhee et al. ADVANCES IN THERAPY
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
- (2015) Graham R. Foster et al. GASTROENTEROLOGY
- Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
- (2015) Edward J. Gane et al. GASTROENTEROLOGY
- Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
- (2015) Nikolien van de Ven et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis
- (2015) Hiromitsu Kumada et al. HEPATOLOGY
- Emerging treatments for chronic hepatitis C
- (2015) C. Nelson Hayes et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
- (2015) Marc Bourlière et al. LANCET INFECTIOUS DISEASES
- Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C
- (2015) Ming-Lung Yu et al. MEDICINE
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
- (2015) Michael P. Curry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) David L. Wyles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
- (2015) Chen-Hua Liu et al. Scientific Reports
- Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial
- (2015) Chen-Hua Liu et al. Scientific Reports
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
- (2014) Pietro Andreone et al. GASTROENTEROLOGY
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
- (2014) Christophe Hézode et al. GUT
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
- (2013) Brian L. Pearlman et al. HEPATOLOGY
- Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
- (2013) Ming-Lung Yu et al. HEPATOLOGY
- Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin
- (2013) Ming-Yao Chen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin
- (2013) Chung-Feng Huang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- APASL consensus statements and management algorithms for hepatitis C virus infection
- (2012) Masao Omata et al. Hepatology International
- Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
- (2012) Ming-Lung Yu et al. PLoS One
- Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1
- (2011) Chung-Feng Huang et al. ANTIVIRAL RESEARCH
- Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future
- (2011) Vincent Di Martino et al. HEPATOLOGY
- Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
- (2011) Chung-Feng Huang et al. JOURNAL OF HEPATOLOGY
- Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
- (2010) Ming-Lung Yu et al. HEPATOLOGY
- Treatment of chronic hepatitis C in Asia: When East meets West
- (2009) Ming-Lung Yu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response
- (2009) Chung-Feng Huang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
- (2008) Chen‐Hua Liu et al. CLINICAL INFECTIOUS DISEASES
- Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
- (2008) Ming-Lung Yu et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now